The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis

Molecular Immunology

Volumn 75, Issue , 2016, Pages 161-167

  Filippidou, Natalia ^a   Krashias, George ^a   Pericleous, Charis ^b   Rahman, Anisur ^b   Ioannou, Yiannis ^b,c   Giles, Ian ^b   Demetriou, Christiana ^a   Anatolitou, Afroditi ^a   Christodoulou, Christina ^a   Pantzaris, Marios ^a   Lambrianides, Anastasia ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Autoantibodies; Autoimmune disease; Multiple sclerosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; RISK FACTOR; VENOUS THROMBOEMBOLISM; BLOOD; IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; AUTOANTIBODIES; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 84975029669     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2016.05.022     Document Type: Article

References (57)

1. Agar C., van Os G.M., Morgelin M., Sprenger R.R., Marquart J.A., Urbanus R.T. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010, 116:1336-1343.
2. Aksungar F.B., Topkaya A.E., Yildiz Z., Sahin S., Turk U. Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J. Clin. Neurosci. 2008, 15:393-397.
3. Bidot C.J., Horstman L.L., Jy W., Jimenez J.J., Bidot C., Ahn Y.S. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007, 7:36.
4. Caronti B., Calderaro C., Alessandri C., Conti F., Tinghino R., Pini C. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J. Autoimmun. 1998, 11:425-429.
5. Chapman J. The interface of multiple sclerosis and antiphospholipid antibodies. Thromb. Res. 2004, 114:477-481.
6. Collard R.C., Koehler R.P., Mattson D.H. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997, 49:857-861.
7. Cousins L., Pericleous C., Khamashta M., Bertolaccini M.L., Ioannou Y., Giles I. Antibodies to domain I of beta-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome. Ann. Rheum. Dis. 2015, 74:317-319.
8. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103:4222-4231.
9. D'Haeseleer M., Cambron M., Vanopdenbosch L. De keyser J: vascular aspects of multiple sclerosis. Lancet Neurol. 2011, 10:657-666.
10. Doerck S., Gobel K., Weise G., Schneider-Hohendorf T., Reinhardt M., Hauff P. Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. PLoS One 2010, 5:e15478.
11. Eikelenboom M.J., Killestein J., Izeboud T., Kalkers N.F., van Lier R.A., Barkhof F. Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. J. Neuroimmunol. 2002, 133:225-232.
12. Ferreira S., D'Cruz D.P., Hughes G.R. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?. Rheumatology (Oxford) 2005, 44:434-442.
13. Fraussen J., Vrolix K., Martinez-Martinez P., Losen M., De Baets M.H., Stinissen P. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun. Rev. 2009, 8:654-658.
14. Fraussen J., Claes N., de Bock L., Somers V. Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun. Rev. 2014, 13:1126-1137.
15. Frohman E.M., Racke M.K. Raine CS: Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
16. Garg N., Zivadinov R., Ramanathan M., Vasiliu I., Locke J., Watts K. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J. Neuroimmunol. 2007, 187:159-165.
17. Giles I., Lambrianides N., Pattni N., Faulkes D., Latchman D., Chen P. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J. Immunol. 2006, 177:1729-1736.
18. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
19. Gutcher I. Becher B: APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 2007, 117:1119-1127.
20. Haines C.J., Chen Y., Blumenschein W.M., Jain R., Chang C., Joyce-Shaikh B. Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Rep. 2013, 3:1378-1388.
21. Hu Z.D., Deng A.M. Autoantibodies in pre-clinical autoimmune disease. Clin. Chim. Acta 2014, 437:14-18.
22. Ijdo J.W., Conti-Kelly A.M., Greco P., Abedi M., Amos M., Provenzale J.M., Greco T.P. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?. Lupus 1999, 8:109-115.
23. Ioannou Y., Giles I., Lambrianides A., Richardson C., Pearl L.H., Latchman D.S. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol. 2006, 6:8.
24. Ioannou Y., Pericleous C., Giles I., Latchman D.S., Isenberg D.A., Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007, 56:280-290.
25. Ioannou Y. Rahman A. Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus 2010, 19:400-405.
26. Iverson G.M., Victoria E.J. Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15542-15546.
27. Karussis D., Leker R.R., Ashkenazi A., Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. Ann. Neurol. 1998, 44:629-634.
28. Koudriavtseva T., Plantone D., Renna R. Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders. J. Neurol. 2014, 261:2028-2029.
29. Koudriavtseva T., D'Agosto G., Mandoj C., Sperduti I. Cordiali-Fei P: High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes. Neurol. Sci. 2014, 35:1737-1741.
30. Koudriavtseva T., Renna R., Plantone D., Mainero C. Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors. Front. Neurol. 2015, 6:63.
31. Koudriavtseva T. Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. Front. Neurol. 2014, 5:119.
32. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun. Rev. 2012, 12:313-317.
33. Marrie R.A., Cohen J., Stuve O., Trojano M., Sorensen P.S., Reingold S. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult. Scler. 2015, 21:263-281.
34. Maurelli M., Bergamaschi R., Candeloro E., Todeschini A. Micieli G: Cerebral venous thrombosis and demyelinating diseases: report of a case in a clinically isolated syndrome suggestive of multiple sclerosis onset and review of the literature. Mult. Scler. 2005, 11:242-244.
35. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
36. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 2011, 7:330-339.
37. Meroni P.L., Chighizola C.B., Rovelli F., Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res. Ther. 2014, 16:209.
38. Mitsdoerffer M., Kuchroo V., Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann. N. Y. Acad. Sci. 2013, 1283:57-66.
39. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
40. Peeters P.J., Bazelier M.T., Uitdehaag B.M., Leufkens H.G., De Bruin M.L., de Vries F. The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink. J. Thromb. Haemost. 2014, 12:444-451.
41. Pericleous C., Miles J., Esposito D., Garza-Garcia A., Driscoll P.C., Lambrianides A. Evaluating the conformation of recombinant domain I of beta(2)-glycoprotein I and its interaction with human monoclonal antibodies. Mol. Immunol. 2011, 49:56-63.
42. Pericleous C., Ruiz-Limon P., Romay-Penabad Z., Marin A.C., Garza-Garcia A., Murfitt L. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford) 2015, 54:722-727.
43. Pericleous C. Rahman A. Domain I: the hidden face of antiphospholipid syndrome. Lupus 2014, 23:1320-1323.
44. Roussel V., Yi F., Jauberteau M.O., Couderq C., Lacombe C., Michelet V. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J. Autoimmun. 2000, 14:259-265.
45. Sheremata W.A., Jy W., Horstman L.L., Ahn Y.S., Alexander J.S., Minagar A. Evidence of platelet activation in multiple sclerosis. J. Neuroinflammation 2008, 5:27.
46. Shoenfeld Y., Meroni P.L., Toubi E. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. Curr. Opin. Rheumatol. 2009, 21:495-500.
47. Somers K., Govarts C., Stinissen P., Somers V. Multiplexing approaches for autoantibody profiling in multiple sclerosis. Autoimmun. Rev. 2009, 8:573-579.
48. Stosic M., Ambrus J., Garg N. Weinstock-Guttman B, Ramanathan M, Kalman B et al: MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J. Neurol. 2010, 257:63-71.
49. Sugiyama Y., Yamamoto T. Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J. Exp. Med. 1996, 178:203-215.
50. Szmyrka-Kaczmarek M., Pokryszko-Dragan A., Pawlik B., Gruszka E., Korman L., Podemski R. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus 2012, 21:412-420.
51. Tourbah A., Clapin A., Gout O., Fontaine B., Liblau R., Batteux F. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch. Neurol. 1998, 55:517-521.
52. Uthman I., Noureldine M.H., Berjawi A., Skaf M., Haydar A.A., Merashli M. Hughes syndrome and multiple sclerosis. Lupus 2015, 24:115-121.
53. Vandenberghe N., Debouverie M., Anxionnat R., Clavelou P., Bouly S. Weber M: Cerebral venous thrombosis in four patients with multiple sclerosis. Eur. J. Neurol. 2003, 10:63-66.
54. Yamaguchi Y., Seta N., Kaburaki J., Kobayashi K., Matsuura E., Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007, 110:4312-4318.
55. Zivadinov R., Ramanathan M., Ambrus J., Hussein S., Ramasamy D.P., Dwyer M.G. Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol. Res. 2012, 34:761-769.
56. de Laat B., Mertens K., de Groot P.G. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat. Clin. Pract. Rheumatol. 2008, 4:192-199.
57. de Laat B., van Berkel M., Urbanus R.T., Siregar B., de Groot P.G., Gebbink M.F. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011, 63:3960-3968.